Esperion Therapeutics Inc at JMP Securities Life Sciences Conference Transcript
Excited to be joined next by Esperion Therapeutics. And with us is Ben Halladay, the company's Chief Financial Officer. It's been an exciting year for Esperion with the presentation of cardiovascular outcomes data for bempedoic acid, which is the company's approved therapy for lowering LDL. Not 100% smooth sailing, as you will talk about with some of your discussions with your partner in Europe.
But I think what's been very, very prominent is the importance of the data, physician's reception to the data, and now already seeing the reaction of prescriptions. So I know am kind of giving a little bit of foreshadowing there, Ben. We just love to get the 30-second overview from you on Esperion and how things are going so far this year.
Yeah, it's been a great year for us, I know, speed bumps included. We read out our CLEAR Outcomes trial in March 4 at ACC, where we presented the full detail. We had a simultaneous publication in the New England Journal of Medicine. And I
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
